Karate Health merges with Progentec to pursue comprehensive disease management solutions for lupus and multiple sclerosis (MS) that combine laboratory testing with digital technologies.
Progentec Diagnostics, Inc. and Karate Health, Inc. announced that they have merged, offering laboratory testing and digital technologies for the diagnosis and management of lupus (SLE), multiple sclerosis (MS), and other autoimmune diseases. The merger is a substantive step towards the Progentec mission of developing comprehensive disease management solutions. Financial details of the transaction were not disclosed.
Karate Health Background
Founded in 2016 by Arif Sorathia and Brett Adelman, Karate Health developed patient empowerment and engagement solutions for people living with multiple sclerosis (MS), rheumatoid arthritis (RA), Crohn’s disease, type 1 diabetes, and other complex conditions.
To date, over 350,000 people have visited the platform, using Stool (a bowel movement tracking app), Tackle Fatigue (a fatigue management app), AutoimmuneOrNot (a symptom tracking tool), FlareCall (voice analysis technology – in development), and health literacy websites to manage their health. Karate Health also collaborated with pharmaceutical company partners to elucidate the patient voice.
Post-Acquisition Plans
The combined entity retains the Progentec name and will be headquartered in Oklahoma City, OK. As part of the merger, Progentec will continue research efforts to evaluate the accuracy and predictive power of blood biomarker laboratory technologies. Progentec’s experienced team of clinical researchers and laboratory operations experts will be joined by Arif Sorathia and Brett Adelman, the co-founders of Karate Health. Sorathia and Adelman will lead digital initiatives including the exploration and development of digital therapeutics, the expansion of direct-to-patient toolkits, and the refinement of 21 CFR Part 11 compliant data-capture tools.
Why It Matters
“Karate Health provided high-quality digital tools directly to patients for personal health tracking. By combining these insights with Progentec’s state-of-the-art diagnostics, we will deliver unparalleled and actionable information to the clinicians tasked with managing autoimmune diseases,” shared Mohan Purushothaman, Ph.D., CEO of Progentec.
